Athanor Capital, LP Xenon Pharmaceuticals Inc. Transaction History

Athanor Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$16.81 - $20.0 $169,394 - $201,540	-10,077 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$13.65 - $21.31 $225,907 - $352,680	-16,550 Reduced 62.15%	10,077 $180,000
Q4 2020 Feb 16, 2021	BUY	$9.49 - $16.04 $19,549 - $33,042	2,060 Added 8.39%	26,627 $410,000
Q3 2020 Nov 16, 2020	SELL	$10.82 - $13.35 $15,158 - $18,703	-1,401 Reduced 5.4%	24,567 $272,000
Q2 2020 Aug 13, 2020	BUY	$10.21 - $14.9 $265,133 - $386,923	25,968 New	25,968 $326,000
Q3 2019 Nov 14, 2019	SELL	$8.74 - $10.51 $88,274 - $106,151	-10,100 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$8.51 - $10.75 $85,951 - $108,575	10,100 New	10,100 $100,000

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.